Table 3.

Before-after comparison of the outcome measures in patient receiving pregabalin ± agomelatine

Outcome of interest	Pregabalin ± Agomelatine (n = 23)	F	P-Value
BPI • Week 0 • Week 4 • Week 8	5.72 ± 1.25 4.21 ± 0.8 3.23 ± 0.97	67.63	< 0.001
RMDQ • Week 0 • Week 4 • Week 8	10.7 ± 4.94 7.65 ± 4.16 5.87 ± 3.82	43.03	< 0.001
SF-36 • Week 0 • Week 4 • Week 8	46.78 ± 13.65 56.43 ± 9.47 62.61 ± 9.99	49.55	< 0.001
HADS • Week 0 • Week 4 • Week 8	14.52 ± 6.02 11.61 ± 4.57 9.74 ± 5.24	14.1	< 0.001
GHQ-28 • Week 0 • Week 4 • Week 8	28.52 ± 8.58 21 ± 7.53 15.43 ± 5.8	90.36	< 0.001

BPI: Brief Pain Inventory; RMDQ: Roland-Morris Disability Questionnaire; SF-36: 36-Item Short Form Survey; HADS: Hospital Anxiety and Depression Scale; GHQ-28: General Health Questionnaire – 28

Data are presented with mean ± SD and analyzed by repeated measure ANOVA and Greenhouse-Geisser correction. A P < 0.05 is considered significant